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CLINICAL INVESTIGATIONS 
I 
Early reperfusion therapy improves left 
ventricular function after acute inferior 
myocardial infarction associated with right 
coronary artery disease 
Quantitative global and regional ventriculographic analysis was performed acutely and 1 week 
later In 46 patients undergoing reperfusion procedures within 6 hours of acute Inferior 
myocardlal lnfarctlon due to rlght coronary artery disease. While serial improvement In global left 
ventricular ejection fraction was not demonstrated for the group, infarct zone regional wall 
motion did Improve (-2.7 +- 0.9 vs -2.3 C? 1.4 SD/chord, p < 0.007). Serial Improvement In 
global ejection fraction was demonstrated in the subgroup of patients treated within 2 hours of 
symptom onset (66 ? 10 vs 62 ? 10%; n = 5; p < 0.03). Infarct zone regional wall motion 
Improved serially only In the subgroup of patients treated within 3 hours of symptom onset 
(-2.4 + 1.1 vs -1.3 + 1.7 SD/chord; n = 11; p < 0.007). Patients wlth Initially patent arteries 
had a higher ejection fraction on follow-up catheterization than did those with inltlally occluded 
vessels (61 f 11 vs 55 + 7%; p < 0.02), and patients with patent arteries at follow-up had a 
higher ejection fraction than did those whose arteries were occluded (60 & g vs 48 2 4%; 
p < 0.0001). We conclude that significant improvement in global and regional left ventricular 
function In patlents with Inferior myocardlal Infarction Is possible when reperfusion therapy is 
begun early or when arterlal patency Is achieved. (AM HEART J 1987;114:261.) 
Eric R. Bates, M.D., Eric J. Topol, M.D., Eva M. Kline, B.S.N., 
Alan B. Langburd, M.D., Anthony Y. Fung, M.D., Joseph A. Walton, Jr., M.D., 
Patrick D.V. Bourdillon, M.D., Robert A. Vogel, M.D., Bertram Pitt, M.D., and 
William W. O’Neill, M.D. Ann Arbor, Mich, 
Prognosis following inferior myocardial infarction is 
significantly better than prognosis following anteri- 
or myocardial infarction.ls3 Inferior infarction is 
associated with a smaller enzyme re1easele3 and a 
higher left ventricular ejection fraction> 5 suggesting 
that less myocardial damage occurs. This is reflected 
clinically by a lower incidence of congestive heart 
failure2e4 and death.‘e3 A major goal of reperfusion 
therapy is to preserve left ventricular function by 
reperfusing ischemic myocardium. It has been sug- 
gested6T7 that improvement in ventricular function is 
inversely proportional to the extent of initial dys- 
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function. Since global left ventricular function rni y 
be relatively normal following inferior infarction; 5 
the extent of myocardial salvage .to be expected fro: n 
reperfusion therapy in these patients may not justi: y 
the risk and expense. 
The purpose of this study was to determine tl e 
effect of acute reperfusion therapy on global ard 
regional left ventricular function in patients wil h 
acute inferior myocardial infarction due to rig1 tt 
coronary artery disease who were treated within 6 
hours of symptom onset. Patients with circumfkx 
coronary artery disease constitute a small minoril y 
of patients with inferior infarction undergong 
reperfusion therapy and were excluded from this 
study because myocardial salvage cannot be adc:- 
quately assessed from single-plane 30-degree right 
anterior oblique ventriculograms.s 
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Table I. Coronary arteriographic results by treatment group 
PTCA SKIPTCA 
(n = 19) (n = 10) 
t-PA t-PAIPTCA 
(n = 11) (n = 6) 
Total 
(n = 46) 
Age 57 f 10 54 * 12 55 i 8 50 + 11 52 f 10 
Initial arterial patency 3 (16%) 6 (60%) 6 (55%) 3 (50%) 18 (39%) 
Final arterial patency 18 (95%) 10 (100%) 11 (100%) 5 (83%) 44 (96%) 
Follow-up arterial patency 15 (79%) 9 (90%) 8 (73%) 4 (67%) 36 (78%) 
Initial arterial % stenosis 99 + 2 92 + 10 85 * 19 97 ?I 4 94 k 11 
Final arterial % stenosis 46 + 21 35 + 10 79 + 16 36 2 29 50 k 26 
Follow-up arterial % stenosis 52 f 30 41 k 24 71 f 29 58 f 31 55 + 30 
PTCA = percutaneous transluminal coronary angioplasty; SK = intravenous streptokinase; t-PA = intravenous tissue-type plasminogen activator. 
METHODS 
Patient selection. From May, 1984, to February, 1986, 
148 patients with acute myocardial infarction by enzymat- 
ic criteria were prospectively enrolled in reperfusion ther- 
apy protocols at the University of Michigan Medical 
Center. Ail underwent cardiac catheterization both acute- 
ly and 7 to 10 days later. Inclusion criteria were: (1) chest 
pain of greater than 20 minutes’ duration, but of less than 
6 hours’ duration, consistent with &hernia and unrelieved 
by sublingual nitroglycerin; (2) at least 1 mm ST segment 
elevation in two contiguous ECG leads; (3) age less than 75 
years. Exclusion criteria for this study were: (1) recent 
history of trauma, surgery, stroke, bleeding or prolonged 
cardiopulmonary resuscitation: (2) previous coronary 
bypass surgery or transmural infarction; (3) cardiogenic 
shock. The right coronary artery was identified as the 
infarct-related artery in 64 patients. Eighteen patients 
were subsequently excluded for the following reasons. 
Follow-up catheterization was not performed in three 
patients who died shortly after reperfusion therapy, in 
three patients who refused the follow-up study, and in 
three patients who underwent immediate coronary bypass 
surgery because of severe triple-vessel disease. Two 
patients were excluded because of previous myocardial 
infarction, while seven others had ventriculograms th&t 
were inadequate for analysis. Thus, 46 patients had acute 
and follow-up contrast ventriculograms suitable for quan- 
titative analysis and they constitute the study group. 
Nineteen were treated with percutaneous transluminal 
coronary angioplasty alone, 10 were treated with intrave- 
nous streptokinase followed by immediate angioplasty, 11 
were treated with intravenous tissue-type plasminogen 
activator alone, and six were treated with tissue-type 
plasminogen activator followed by immediate angioplasty. 
These protocols were approved by the University of 
Michigan Institutional Review Board. Informed consent 
was obtained from each patient. 
interventional protocols 
1. Intravenous lytic therapy. Patients receiving strep- 
tokinase were premeditated with intravenous hydrocorti- 
sone, 200 mg, and were then given a total of 1.5 million U 
of streptokinase over 30 minutes, following a test dose. 
Patients receiving tissue-type plasminogen activator were 
given 0.75 mg/kg over 1 hour and 0.5 mg/kg over the 
subsequent 2 hours, for a total dose of 1.25 mg/kg over 3 
hours. The recombinant tissue-type plasminogen activa- 
tor was predominately a single-chain preparation (Genen- 
tech, San Francisco, Calif.) 
2. Angiography. Vascular sheaths were placed in a 
femoral artery and vein and 5000 U of intravenous heparin 
was administered. By means of the Judkins technique, 
selective coronary arteriography was performed in multi- 
ple projections and then ventriculography was performed 
in the 30-degree right anterior oblique projection. 
3. Angioplasty. Patients receiving angioplasty were 
given an additional 5000 U of intravenous heparin. The 
procedure was performed only in the infarct vessel with a 
steerable guidewire and balloon catheter system. 
4. Hospital course. Therapeutic heparin infusion was 
continued until repeat angiography was performed 7 to 10 
days later, except for a few hours on the second hospital 
day when the vascular sheaths were removed. Patients 
were also treated with aspirin, 325 mg one to three times 
per day, dipyridamole, 75 mg three times per day, and 
diltiazem, 30 mg four times per day. 
Analysis of left ventricular function. To measure left 
ventricular function, end-diastolic and end-systolic out- 
lines were independently projected and traced by two 
blinded experienced angiographers from a non-postpre- 
mature normal sinus beat. Global ejection fraction was 
determined by means of the area-length method? When 
results obtained by the two determinations differed by 
more than 5%) a joint determination of outlines was 
performed. Regional wall motion was determined by the 
centerline method.10s11 Briefly, 100 equally spaced chords 
are constructed perpendicular to a centerline drawn mid- 
way between the end-diastolic and end-systolic outlines. 
Motion along the perpendicular lines is normalized for 
centerline length and is expressed in unita of standard 
deviation of mean wall motion obtained from ventriculo- 
graphic analysis of 64 normal subjects.‘O Regional wall 
motion is calculated as the mean motion of chords lying in 
the most hypolcmetic 50% of the infarct zone or the most 
hyperkinetic 50% of the non-infarct zone, and is ex- 
pressed in standard deviations per chord. Negative and 
positive values are respectively hypokinetic and hyperki- 
netic compared with normal mean wall motion. 
Statistical analysis. Results are expressed as mean -+ 
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Fig. 1. Change in ejection fraction in acute and follow- 
up studies in each patient group. PTCA = percutaneous 
transluminal coronary angioplasty; SK = intravenous 
streptokinase; t-PA = intravenous tissue-type plasmino- 
gen activator. 
SD. Paired t tests were performed to compare initial and 
follow-up values. Unpaired t tests were used for inter- 
group comparisons. A probability (p) value of less than 
0.05 was considered statistically significant. 
RESULTS 
Coronary arteriography (Table I). The initial arterio- 
gram revealed right coronary artery patency with 
good visualization of the distal vessel in 18 of 46 
(39%) patients. Those studied after intravenous 
lytic therapy had a higher initial patency rate than 
those who had not received lytic therapy (15 of 27 vs 
3 of 19, p < 0.007). The last arteriogram following 
completion of reperfusion therapy demonstrated 
arterial patency in 44 of 46 (96%) patients. Patency 
1 week later was demonstrated in 36 of 46 (78%) 
patients. 
Arterial percent stenosis of the infarct-related 
artery was significantly less following reperfusion 
therapy in patients treated with angioplasty com- 
pared to patients treated only with lytic therapy 
(41 rtr 21 vs 79 & 16, p < 0.03). Arterial percent ste- 
nosis 1 week later increased slightly in each group 
due to inclusion of patients with arterial reocclu- 
sion. 
Ventricular function by treatment group (Figs. 1 and 
2, Table II). No significant serial improvement in 
ejection fraction between the initial and follow-up 
studies was found for the total group. However, 
PTc4 SK/PTCA t-PA 







Fig. 2. Change in regional wall motion in the infarct zone 
in acute and follow-up studies in each patient group. 
Abbreviations as in Fig. 1. 
patients treated with streptokinase plus angioplasty 
did experience an improvement in ejection fraction 
(60 f 8% vs 65 + 7%, p < 0.005). Importantly, 
time to treatment in this group was at least 93 
minutes sooner than treatment in the other 
groups. 
Regional wall motion in the infarct zone improved 
significantly only in the streptokinase plus angio- 
plasty group (-2.6 + 1.0 vs -1.5 +- 1.7 SD/chord, 
p < 0.02) and in the total group (-2.7 + 0.9 vs 
-2.3 f 1.4 SD/chord, p < 0.007). Regional wall 
motion in the non-infarct zone did not change in any 
group. 
Ventricular function by time to treatment (Table III). 
Patients treated less than 2 hours from symptom 
onset had serial improvement in ejection fraction 
(55 & 10 vs 62 & lo%, p < 0.03), while those 
treated after 2 hours did not. Improvement in 
infarct zone regional wall motion was found only in 
patients treated within 3 hours of symptom onset 
(-2.4 f 1.1 vs -1.3 + 1.7 SD/chord, p < 0.007). 
Ventricular function by patency status (Table IV). 
Neither initial nor follow-up arterial patency were 
associated with serial improvement in ejection frac- 
tion. On follow-up catheterization, however, pa- 
tients with initially patent arteries had a higher 
ejection fraction than did those with initially occlud- 
ed arteries (61 & 11 vs 55 + 7%) p < 0.02), and 
patients with persistently patent arteries had a 
higher ejection fraction than did those whose arter- 
ies were occluded (60 + 9 vs 48 + 4%) p < 0.0001). 
Serial improvement in infarct zone regional wall 
Table ft. Global and regional left ventricular function by treatment group 
PTCA ~K~FTCA t-PA t-iA/PTCA 
(n = 19) in = 10) (n = II) (n = 6) 
Ejection fraction (%) 
ACUte 55 -t a 60 f 8 57 2 8 56 2~ 13 
Follow-up 55 + 5 651r7 55 z!z 10 59 + 12 
Del&l -0.5 + 8 4.5 -t 4 -2.5 i 8 3 2 11 
p Value NS 0.005 NS NS 
Regional wall motion (SD/chord) infarct zone 
Acute -2.5 it: 0.8 -2.6 J- 1.0 -2.9 I 0.6 -3.0 2 1.0 
Follow-up -2.4 -f- 0.9 -1.5 It 1.7 -2.8 f I.1 -2.1 4 2.0 
Delta 0.1 r 0.7 1.1 rt 1.3 0.1 i LO 1.0 * 1.2 
p Value NS 0.02 NS NS 
Regianal wall motion (SD/chord) non-infarct zone 
Acute 1.1 2 1.4 1.9 r 1.1 0.3 AZ 1.6 0.1 2 1.3 
FQ~lOW-up 0.8 + 1.1 1.6 + 1.1 0.2 I- 1.4 0.4 + 1.6 
Delta -0.4 +- 1.3 -0.1 2 0.4 -0.1 r?l 1.2 0.2 It 1.0 
p Value NS NS NS NS 
Time to treatment fmin) 254 + 59 135 +- 68 228 2 44 257 " 44 
Delta = difference between acute and follow-up values; NS = not significant; other abbreviations as in Table I. 
--~- 
Total 
fn = 461 
57 * 9 
57 I9 
0.5 T 8 
NS 
-2.7 +- 0.9 
-2.3 1 1.4 
0.4 -1- 1.1 
0.007 
1.0 + 1.5 
0.8 i 1.4 
-0.2 f 1.1 
NS 
222 -e 74 
~- 
Yable Ill. Global and regional left ventricular function by 
time to treatment 
<2hr(n=5) <3hr(n=fl) r3hr{n=35) 
Ejection fraction f J f 
Acute 55 f 10 59 2 10 56 xk 9 
Follow-up 62 + 10 63 + 9 56 i- 9 
Delta '7.5 + 6 3.5 rt 7 -0.5 k 9 
p value 0.03 NS NS 
Reg&m?l wail motion ~S~/~~O~~ infarct zone 
Acute -2.0 t 0.6 -2.4 z!z 1.1 -2.7 f 0.8 
Follow-up -0.2 rt 1.5 -1.3 rk 1.7 -2.5 z!z 1.2 
Delta 1.9 2 1.1 1.1 rtr 1.2 -0.2 i: 1.0 
p Value 0.01 0.007 NS 
Regional wall motion (SD/chord) non-infarct zone 
Acute l.3 f 0.9 1.4 rt 1.5 0.8 4 15 
Follow-up 0.8 iz 1.1. 1.4 t 1.5 0.6 + 1.3 
Delta -0.5 2 0.5 0 0.2 I 1.2 
p Value NS NS NS 
Abbreviations as in Table II. 
motion occurred in patients with both initially 
patent (-2.2 t 0.9 vs -1.3 1 1.7 SD/chord, 
p < 0.006) and pe~is~nt~y patent arteries (-2.6 2 
0.9 va -2.0 + 1.5 SD/chord, p < 0.003). No improve- 
ment occurred in patients with initially occluded or 
pe~is~~tly occluded arteries. Patients with initially 
patent arteries had bettor infarct zone regional wall 
motion than did those with initially occluded arter- 
ies, both initially (-2.2 + 0.9 vs -3.0 + 0.8 SD/ 
chord, p < 0.002) and at follow-up (-1.3 f 1.7 vs 
-2.9 rk: 0.8 SD/chord, p < 0,OOOl). Patients with 
~~~~n~y patent arteries had better infarct zone 
regional wall motion than did those with persistent- 
ly occluded arteries at follow-up (-2.0 4 1.5 vs 
-3.1 + 0.4 SD/chord, p < 0.01). 
DI§ClJSSlON 
Global e@ctlon fraction. Although the Western 
Washington randomized, controlled trial demon- 
strated no improvement in left ventricular ejection 
fraction when streptokinaae therapy was given 
approximately 5 hours after symptom onset in acute 
myocardial infarction,12*13 a more recent trial by 
Serruys et aLX4 with streptoKmase administered 
within 3 hours of symptom onset in patients without 
previous infarction did show a significant improve- 
ment in ejection fraction compared to the control 
group, both in patients with inferior infarction and 
anterior infarction. 
More controversial is whether streptokinase ther- 
apy results in further improvement in ejection frac- 
tion on serial testing following the acute ejection 
fraction determination. While analysis of patients 
with ~~~~nt~y patent arteries in ~~ontro~~d 
studies have shown serial improvement in ejection 
fraction,16-18 patients an&xed by the intention-to- 
treat principle I*, lgs20 have not. Additionally, studies 
that used the area length method of contrast ven- 
tri~~~aphic analysis employed in this studyX”*” 
have not shown serial improvement in ejection 
fraction. This discrepancy is not explained by the 
route of streptokinase administration or by time to 
treatment differences, No serial improvement in 
ejection fraction following inferior infarction has 
previously been demonstrated.‘** n* 23 
A severe residual stenosis following thrombolysis 
has heen shad to limit ~~tiun~ recovery. Re- 
st&ted blood flow or ~t~rn~~ and rei~~ction 
may explain why serial improvement in ejection 
fraction is not co~sis~~tly found after &tic thera- 
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Table IV. Global and regional left ventricular function by patency status 
Initial status Follow-up status 
Patent (n = 18) Occluded (n = 28) p Value Patent (n = 36) Occluded (n = 10) p Value 
Ejection fraction ( % ) 
Acute 59 zk 10 56 + 8 
Follow-up 61 f 11 55 + 7 
Delta 2+9 -1 f 8 
p Value NS NS 
Regional wall motion (SD/chord) infarct zone 
Acute -2.2 f 0.9 -3.0 + 0.8 
Follow-up -1.3 * 1.7 -2.9 -t 0.8 
Delta 0.9 + 1.4 0.1 +- 0.7 
p Value 0.006 NS 
Regional wall motion (SD/chord) non-infarct zone 
Acute 0.8 zt 1.7 1.2 f 1.4 
Follow-up 0.4 * 1.5 1.1 f 1.3 
Delta -0.3 -0.1 
p Value NS NS 
Abbreviations as in Table II. 
NS 59 iz 9 51 + 8 0.008 
0.02 60 k 9 48 + 4 0.0001 
NS 128 -2.5 f 10 NS 
NS NS 
0.002 -2.6 f 0.9 -3.0 k 0.5 NS 
0.0001 -2.0 + 1.5 -3.1 + 0.4 0.01 
0.005 0.6 k 1.2 -0.1 + 6 0.04 
0.003 NS 
NS 1.1 + 1.6 0.5 + 1.3 NS 
NS 0.9 + 1.5 0.4 rfc 1.0 NS 
NS -0.2 k 1.2 -0.2 c 0.8 NS 
NS NS 
py.7~24~25 Interestingly, preliminary evidence suggests 
that when angioplasty14s 26, 27 or coronary bypass sur- 
geryz8 follows lytic therapy, serial ejection fraction 
does improve. Our data also show that early lytic 
therapy followed by angioplasty can result in serial 
ejection fraction improvement in inferior infarction, 
while late treatment with lytic therapy and/or angio- 
plasty does not. Regardless of whether or not serial 
improvement in ejection fraction occurs, it should be 
emphasized, both in our own and previous studies, 
that successful reperfusion with a documented 
patent vessel prior to hospital discharge results in a 
higher ejection fraction than is found with an 
occluded infarct-related artery. 
Regional wall motion. As reported for ejection frac- 
tion, regional wall motion was not improved by 
reperfusion therapy in the Western Washington 
Study, in which streptokinase was given approxi- 
mately 5 hours after symptom onset,12~13 while it was 
improved in the study by Serruys et al.,14 in which 
streptokinase was administered within 3 hours of 
symptoms. All the nonrandomized studies that 
reported either presence or absence of serial 
improvement in ejection fraction following reperfu- 
sion therapy reported serial improvement in region- 
al wall motion.15-21 Those that did not find serial 
improvement in ejection fraction found that com- 
pensatory hyperkinesia in the non-infarct zone often 
preserved initial ejection fraction despite severe 
hypokinesia in the infarct zone, thus masking poten- 
tial global improvements. 11* ls* ” Serial improvement 
in infarct zone regional wall motion after inferior 
infarction has been reported for patients with patent 
arteries7~‘5~23 and for patients receiving streptoki- 
nase.14 Our data also show improvement in infarct 
zone regional wall motion, particularly in patients 
treated with streptokinase plus angioplasty. Time to 
treatment and patency staus were strong predictors 
of improvement. 
Limitations. This study is limited by the fact that 
small groups of patients were treated by different 
interventions and that treatment was delayed in 
patients treated by angioplasty alone or by tissue- 
type plasminogen activator. These limitations 
reflect the rapid evolution of reperfusion therapy in 
our catheterization laboratory from direct angio- 
plasty20 to intravenous streptokinase followed by 
immediate angioplasty2s to intravenous tissue-type 
plasminogen activator with subsequent randomiza- 
tion to delayed angioplasty or immediate angioplas- 
ty.30 While patients treated with streptokinase 
received early therapy in their local emergency 
rooms, patients receiving direct angioplasty or tis- 
sue-type plasminogen activator had to be sent by 
ground or helicopter transport to our catheterization 
laboratory before treatment could be instituted, 
thus explaining the differences between groups in 
time to treatment. In spite of these limitations, 
improvement in ventricular function by reperfusion 
therapy in inferior infarction was demonstrated by 
this study. Earlier therapy would be expected to 
produce more dramatic improvement.“, 15-17, 21* 22* 31 
Not enough patients were treated with tissue-type 
plasminogen activator plus angioplasty to demon- 
strate a statistically significant improvement in ven- 
tricular function, although the serial changes 
obtained were similar to those in the streptokinase 
plus angioplasty group. Time to treatment was 2 
266 Bates et al. 
hours later, however, and was equivalent to patients 
treated only with either tissue-type plasminogen 
activator or with angioplasty who did not show 
improvement in ventricular function. More patients 
will have to be studied to determine if this form of 
sequential therapy provides a longer time frame 
within which reperfusion therapy can be applied 
with expectation of myocardial salvage. 
Three patients died before the follow-up study 
could be obtained. All were clinically stable before 
reperfusion of a proximal arterial occlusion and then 
deteriorated rapidly, dying within 24 hours of hospi- 
talization. This course of events has not occurred in 
our experience with reperfusion therapy in proximal 
left anterior coronary arteries. The hemodynamic 
sequelae of right ventricular infarction probably 
result from interruption of proximal right coronary 
artery blood flow to the crista supraventricularis.32 It 
is possible that the right ventricle is particularly 
susceptible to reperfusion injury33 and that this 
contributed to the demise of these patients. 
Clinical implications. It is increasingly clear that 
reperfusion therapy in acute myocardial infarction 
has the potential to preserve left ventricular func- 
tion14-23* 26-31 and decrease mortality.22* 34 Data from 
this study and others demonstrate that myocardial 
salvage is critically dependent upon time to treat- 
ment and upon restoring arterial patency, and is not 
related to location of infarction. It is also probable 
that early angioplasty after lytic therapy is impor- 
tant in salvaging myocardium by preventing arterial 
reocclusion or by achieving acute arterial patency in 
arteries not reperfused by lytic therapy. 
The effort and expense required to apply reperfu- 
sion therapy to all patients with acute infarction 
would require a major allocation of additional re- 
sources to the cardiac catheterization laboratory and 
regionalization of health care delivery. If treatment 
could be limited to subgroups of patients most likely 
to benefit from this form of therapy, the risk and 
expense could be reduced. Unfortunately, such sub- 
groups have not yet been clearly defined. While 
therapy is better given earlier than later, intermit- 
tent coronary occlusion or the presence of collateral 
blood flow cannot be predicted noninvasively and 
extend the time frame within which myocardial 
salvage can be achieved. Although it has been 
suggested that ECG criteria23T35 or initial reduced 
ejection fraction36 predict larger infarct size and 
patients with inferior infarction more likely to ben- 
efit from lytic therapy, we could not confirm those 
findings in our patients, most of whom had angio- 
plasty. Until more rigorous selection criteria can be 
formulated based upon mortality data in prospec- 
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tive randomized trials, the data from the current 
study suggest that reperfusion therapy in patients 
with inferior myocardial infarction who present 
within 3 hours of symptom onset with ST segment 
elevation in at least two contiguous ECG leads will 
improve left ventricular function. Additional data 
are required to determine whether patient survival 
is also increased. 
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